Fig. 1: Prevalence of anti-SARS-CoV-2 IgG antibodies across study groups and validation of the results. | Nature Communications

Fig. 1: Prevalence of anti-SARS-CoV-2 IgG antibodies across study groups and validation of the results.

From: Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Fig. 1

a Left: Prevalence and 95% confidence intervals of a positive anti-SARS-CoV-2 IgG antibody test recognizing the S1 domain of the spike protein in the non-health care (NHC) control cohort, health care (HC) control cohort and immune-mediated inflammatory diseases (IMIDs) with and without cytokine inhibitors (CI); right: risk ratios and 95% confidence intervals of anti-SARS-CoV-2 IgG antibody positivity in the HC control cohort and IMIDs with and without cytokine inhibitors (CI) with the NHC control cohort as reference; b Comparison of anti- SARS-CoV-2 IgG positive (anti-S1+; N = 10) and negative (anti-S1; N = 10) samples (in Euroimmune ELISA) for reactivity in the chemi-luminescent anti- SARS-CoV-2 Spike S1/nucleocapsid IgG test (Yhlo Biotech) and anti-nucleocapsid IgG antibody ELISA (Immundiagnostik Inc). c Validation with in-house ELISA testing reactivities against1 the S1 domain of the spike protein2, the receptor binding domain (RBD) of the S1 domain of the spike protein3, extracellular domain (ECD) of the S2 domain of the spike protein and4 the nucleocapsid in anti- SARS-CoV-2 IgG negative (N = 6) and positive (N = 6) samples (in Euroimmune ELISA), COVID-19 patients with positive viral RNA test (N = 6) and patients with endemic human coronavirus (HCoV) infection (N = 5) in the pre- SARS-CoV-2 time.

Back to article page